Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial

Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial

Abstract Background In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior. We performed a prospective, open-label, non-comparative phase II study to assess survival with HAIC or HAIC converte...

Full description

Bibliographic Details
Main Authors: Masahiro Hatooka, Tomokazu Kawaoka, Hiroshi Aikata, Yuki Inagaki, Kei Morio, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Kazuo Awai, Keiichi Masaki, Koji Waki, Hirotaka Kohno, Hiroshi Kohno, Takashi Moriya, Yuko Nagaoki, Toru Tamura, Hajime Amano, Yoshio Katamura, Kazuaki Chayama
Format: Article
Language:English
Published: BMC 2018-06-01
Series:BMC Cancer
Subjects:
HCC
HAIC
Sorafenib
Tumor marker
RECIST
Online Access:http://link.springer.com/article/10.1186/s12885-018-4519-y

Internet

http://link.springer.com/article/10.1186/s12885-018-4519-y

Similar Items